Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

And other biotech news brought to you by The Readout.

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

Recent regulatory changes could cause a “massive delay” in cancer drug approvals, but Big Pharma is willing to cooperate with the FDA, SVB Securities' Daina Graybosch said. 2023 forecast: FDA ...

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease.

The FDA accepted a BLA for Blenrep combinations for multiple myeloma treatment after prior therapy. DREAMM-7 and DREAMM-8 trials showed significant improvements in progression-free survival and ...

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.